Chimerix Appoints Michelle Berrey Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2012
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2012 /PRNewswire/ -- Chimerix, Inc., a
biotechnology company developing orally-available antiviral therapeutics,
announced today that Michelle Berrey, MD, MPH, has joined the company as Chief
"We are delighted to have Michelle joinourleadership team.Dr. Berreyis a
seasoned drug developer whohas established a strong track record in
antivirals, in particular with nucleotide analogs. Shejoins Chimerix at an
important time for the company as our lead compound,CMX001,advances
intoPhase 3clinical testing,"saidKenneth I. Moch, ChimerixPresident and
ChiefExecutive Officer. "Her extensive background in antiviral drug
development willbeinvaluable to our already strong team."
Prior to joining Chimerix, Dr. Berrey was Chief Medical Officer at Pharmasset,
Inc., a company that focused on the development of nucleotide analogs for the
treatment of hepatitis C, from 1997 until its acquisition by Gilead Sciences,
Inc. in January 2012. Dr. Berrey's experience includes the design, early
development, medical governance, clinical strategy and product life cycle
management of antiviral products.
Previously, Dr. Berrey was Vice President, Viral Diseases, Clinical
Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was
responsible for the early development of compounds for the treatment of HIV,
hepatitis viruses and hepatic fibrosis.
Dr. Berrey received her M.D. from the Medical College of Georgia and a Master
of Public Health from Emory University. She completed her internship and
residency in Internal Medicine at the University of North Carolina, Chapel
Hill, and was a Senior Fellow in Infectious Diseases at the University of
Washington, Seattle, where she conducted research in HIV transmission and
acute HIV infection.
Chimerix is developing novel oral antiviral therapeutics with the potential to
improve outcomes for patients in multiple therapeutic areas, including
transplant, oncology, acute care and global health. The Company's proprietary
lipid technology has given rise to two clinical-stage lipid acyclic nucleoside
phosphonates that have demonstrated the potential for enhanced activity and
safety compared with currently approved drugs.
Chimerix's lead clinical-stage drug candidate, CMX001, is a novel,
broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA)
viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and
herpes simplex virus. CMX001 has completed Phase 2 clinical development for
the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients
and is in Phase 2 development for the preemption and treatment of AdV
infection. To date, more than 800 patients have been dosed with CMX001 in
controlled clinical trials and open-label treatment protocols. Chimerix has
completed an End of Phase 2 meeting with the U.S. Food and Drug Administration
and is preparing to initiate Phase 3 clinical development of CMX001 for the
prophylaxis of CMV in HSCT recipients in 2013.
In addition to its commercial use, CMX001 is being developed under a contract
from the Biomedical Advanced Research and Development Authority (BARDA) as a
medical countermeasure to protect against a bioterror threat in the event of a
In July 2012, Chimerix granted an exclusive worldwide license to Merck for the
development and commercialization of its second clinical-stage drug candidate,
CMX157, for the treatment of HIV infection, further validating the Company's
propriety lipid technology.
For more information, please visit www.chimerix.com.
SOURCE Chimerix, Inc.
Contact: Rebecca Heath, +1-919-972-7124; Elizabeth Kelly, +1-919-972-7109;
Media: Laura Bagby, +1-646-964-5852, firstname.lastname@example.org; Investors: Rachel
Hunter, +1-212-362-1200, email@example.com
Press spacebar to pause and continue. Press esc to stop.